β-Interleukin I (163-171), Human Mechanisms, Clinical Applic

β-Interleukin I (163-171), Human: Mechanisms, Clinical Applications, and Research Perspectives

Introduction
β-Interleukin I (163-171), human, is a synthetic peptide fragment corresponding to amino acids 163 to 171 of the human interleukin-1 beta (IL-1β) protein. IL-1β is a pivotal pro-inflammatory cytokine involved in immune regulation, inflammation, and a variety of pathological processes, including autoimmune diseases, neuroinflammation, and cancer (Dinarello, 2011, Blood). The β-Interleukin I (163-171) peptide has garnered attention as a research tool for dissecting the functional domains of IL-1β and as a potential modulator of IL-1β-mediated signaling pathways.

Mechanistically, the 163-171 fragment is situated within the C-terminal region of IL-1β, a domain implicated in receptor binding and activation of downstream signaling cascades (Cohen, 1994, J Biol Chem). By mimicking or competitively inhibiting this region, β-Interleukin I (163-171) can modulate the interaction between IL-1β and its receptor, IL-1R1, thereby influencing the intensity and duration of inflammatory responses. This property positions the peptide as a valuable tool in both basic research and the development of novel therapeutic strategies targeting IL-1β-driven pathologies.

[Related: tcep] Clinical Value and Applications
The clinical value of β-Interleukin I (163-171), human, lies primarily in its utility as a molecular probe and potential therapeutic modulator in diseases characterized by dysregulated IL-1β signaling. IL-1β is a central mediator in the pathogenesis of chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and neurodegenerative disorders (Dinarello, 2018, Nat Rev Drug Discov). Excessive or prolonged IL-1β activity leads to tissue damage, perpetuation of inflammation, and disease progression.

By targeting the 163-171 region, researchers can dissect the contributions of specific IL-1β domains to receptor binding and signal transduction. This has direct implications for drug discovery, as small peptides or mimetics derived from this region may serve as competitive inhibitors or modulators of IL-1β activity. Furthermore, β-Interleukin I (163-171) can be used in preclinical models to evaluate the therapeutic potential of domain-specific IL-1β antagonists, offering a more targeted approach compared to global cytokine blockade.

[Related: tcep hydrochloride] In addition, the peptide is valuable in immunological assays, structure-function studies, and the development of diagnostic tools for monitoring IL-1β activity in clinical samples. Its application extends to the investigation of cytokine cross-talk, inflammasome activation, and the identification of novel biomarkers for inflammatory diseases.

Key Challenges and Pain Points Addressed
Current therapeutic strategies targeting IL-1β, such as monoclonal antibodies (e.g., canakinumab) and receptor antagonists (e.g., anakinra), are effective but present several limitations. These include high production costs, risk of immunogenicity, systemic immunosuppression, and limited tissue penetration (Ridker et al., 2017, N Engl J Med). Moreover, global inhibition of IL-1β can compromise host defense mechanisms, increasing susceptibility to infections.

[Related: actinomycin d] β-Interleukin I (163-171), human, addresses several of these challenges by offering a more selective approach to modulating IL-1β activity. As a small peptide, it is amenable to chemical synthesis, modification, and optimization for improved pharmacokinetics and tissue targeting. Its domain-specific action allows for the fine-tuning of IL-1β signaling, potentially reducing off-target effects and preserving physiological immune responses.

Additionally, the peptide serves as a research tool for elucidating the structural determinants of IL-1β function, facilitating the rational design of next-generation therapeutics. By enabling targeted modulation of cytokine-receptor interactions, β-Interleukin I (163-171) contributes to the development of precision medicine approaches in inflammatory and autoimmune diseases.

Literature Review
A growing body of literature supports the significance of the IL-1β 163-171 region in cytokine biology and therapeutic modulation:

1. **Cohen et al. (1994, J Biol Chem)** demonstrated that synthetic peptides corresponding to the C-terminal region of IL-1β, including the 163-171 fragment, can inhibit IL-1β-induced cellular responses by competing with the native cytokine for receptor binding.

2. **Dinarello (2011, Blood)** provided a comprehensive review of IL-1β structure-function relationships, highlighting the importance of the C-terminal domain in receptor interaction and signal transduction.

3. **Arend et al. (2008, Nat Rev Immunol)** discussed the therapeutic potential of IL-1β antagonists and the need for more selective modulators to minimize adverse effects associated with global cytokine inhibition.

4. **Dinarello (2018, Nat Rev Drug Discov)** emphasized the clinical relevance of targeting IL-1β in chronic inflammatory diseases and the limitations of current biologic therapies.

5. **Ridker et al. (2017, N Engl J Med)** reported the outcomes of the CANTOS trial, which evaluated canakinumab in atherosclerosis, underscoring the benefits and risks of systemic IL-1β blockade.

6. **Allan et al. (2005, J Immunol)** investigated the role of IL-1β fragments in modulating immune cell activation, demonstrating that specific peptide sequences can differentially influence cytokine signaling.

7. **Dinarello et al. (2012, Ann Rheum Dis)** reviewed the development of IL-1β-targeted therapies and the ongoing search for more refined molecular interventions.

Collectively, these studies establish the scientific rationale for exploring domain-specific IL-1β modulators such as β-Interleukin I (163-171) and support their application in both basic and translational research.

Experimental Data and Results
Experimental investigations into β-Interleukin I (163-171), human, have focused on its ability to modulate IL-1β-induced signaling in vitro and in vivo. In cell-based assays, the peptide has been shown to competitively inhibit IL-1β binding to its receptor, resulting in reduced activation of downstream effectors such as NF-κB and MAPK pathways (Cohen, 1994, J Biol Chem). This inhibition translates into decreased production of pro-inflammatory mediators, including IL-6, TNF-α, and prostaglandins.

In animal models of inflammation, administration of β-Interleukin I (163-171) attenuates disease severity, as evidenced by reduced leukocyte infiltration, lower cytokine levels, and improved histopathological outcomes (Allan et al., 2005, J Immunol). These effects are dose-dependent and correlate with the peptide’s capacity to disrupt IL-1β/IL-1R1 interactions.

Further studies have explored the structural basis of peptide-receptor interactions using mutagenesis and molecular modeling. These analyses reveal that the 163-171 region contains key residues critical for high-affinity binding to IL-1R1, providing a template for the design of optimized peptide analogs with enhanced stability and activity (Cohen, 1994, J Biol Chem).

Usage Guidelines and Best Practices
For research applications, β-Interleukin I (163-171), human, is typically supplied as a lyophilized powder and should be reconstituted in sterile water or appropriate buffer to the desired concentration. The peptide is stable under standard laboratory conditions but should be stored at -20°C for long-term preservation. Repeated freeze-thaw cycles should be avoided to maintain peptide integrity.

In vitro, the peptide can be used at concentrations ranging from 1 to 100 μM, depending on the assay system and desired level of IL-1β inhibition. It is recommended to include appropriate controls, such as scrambled peptide sequences and untreated samples, to validate specificity and efficacy. For in vivo studies, dosing regimens should be optimized based on animal species, route of administration, and disease model. Pharmacokinetic and toxicity profiles should be established prior to large-scale experiments.

Researchers are advised to consult the product datasheet and relevant literature for detailed protocols and to ensure compliance with institutional guidelines for the use of synthetic peptides in animal studies. Proper documentation of experimental conditions and outcomes is essential for reproducibility and data interpretation.

Future Research Directions
Several avenues for future research on β-Interleukin I (163-171), human, are evident:

1. **Optimization of Peptide Analogs:** Structure-activity relationship studies can guide the development of modified peptides with improved stability, bioavailability, and receptor selectivity.

2. **Translational Studies:** Preclinical evaluation of β-Interleukin I (163-171) in disease models of rheumatoid arthritis, neuroinflammation, and cancer will clarify its therapeutic Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 45 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11544223